Caldwell David J, Evans Jeffery D
Assistant Professor of Clinical and Administrative Sciences ULM College of Pharmacy, 1800 Bienville Drive, Monroe, LA 71201, USA.
Expert Opin Pharmacother. 2008 Dec;9(18):3231-42. doi: 10.1517/14656560802576324.
Maraviroc is the only approved CCR5 coreceptor antagonist on the market for treatment of HIV-1 infection. It uses a previously untargeted step in the HIV-1 replication cycle necessary for viral entry into the host cell.
This review will describe and evaluate recent clinical literature regarding maraviroc, focusing on safety, efficacy, and mechanisms of treatment failure.
A search of the primary literature and conference abstracts was conducted using the keywords CCR5 antagonist, maraviroc, and UK-427857. Resulting articles were then compiled and analyzed in this review.
Maraviroc is a potent inhibitor of HIV-1 replication and contributes to effective viral suppression in combination with traditional antiretroviral medications. Due to its numerous drug interactions, potential for severe adverse events, and relative paucity of clinical data in long-term randomized, controlled trials, maraviroc should be one of the final agents utilized in salvage therapy in combination with other active antiretroviral agents.
马拉维若（maraviroc）是市场上唯一获批用于治疗HIV-1感染的CCR5共受体拮抗剂。它作用于HIV-1复制周期中病毒进入宿主细胞所必需的一个此前未被靶向的步骤。
本综述将描述和评估近期有关马拉维若的临床文献，重点关注安全性、疗效及治疗失败机制。
使用关键词CCR5拮抗剂、马拉维若和UK-427857检索原始文献和会议摘要。然后对检索到的文章进行汇总并在本综述中进行分析。
马拉维若是HIV-1复制的强效抑制剂，与传统抗逆转录病毒药物联合使用有助于有效抑制病毒。由于其存在众多药物相互作用、有发生严重不良事件的可能性且长期随机对照试验中的临床数据相对较少，马拉维若应是与其他活性抗逆转录病毒药物联合用于挽救治疗的最后使用的药物之一。
